Novartis Corporation Drug Fails To Stop Atrial Fibrillation, ANMCO Research Center Study
BOSTON, April 15 (Reuters) - A high dose of Novartis's (NOVN.VX) blood pressure drug Diovan failed to prevent recurrences of atrial fibrillation, the common irregular beating of the heart that can increase the risk of stroke, Italian researchers reported on Wednesday.